Key facts
- This page summarizes Scot Michael Elder's Form 4 filing for TREACE MEDICAL CONCEPTS, INC. (TMCI).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 12 Jan 2024, 21:00.
Scot Michael Elder - 10 Jan 2024 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)
- Reporting relationship
- *Chief Legal & Compliance Officer, Corporate Secretary
- Issuer ticker
- TMCI
- Reported as of
- 10 Jan 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 12 Jan 2024, 21:00:21 UTC
- Prior SEC filing
- 03 Nov 2023
- Next SEC filing
- 12 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lisa Taylor as Attorney-in-fact for Scot Elder
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Scot Michael Elder filed Form 4 for TREACE MEDICAL CONCEPTS, INC. (TMCI) on 12 Jan 2024.
Change
- Previous filing in this sequence was filed on 03 Nov 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TMCI
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +61,300
- Change %
- +125%
- Price
- $0.000000
- Shares after
- 110,210
- Date
- 10 Jan 2024
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TMCI
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +69,050
- Change %
- Price
- $0.000000
- Shares after
- 69,050
- Date
- 10 Jan 2024
- Ownership
- Direct
- Underlying class
- Stock Option (Right to Buy)
- Underlying amount
- 69,050
- Exercise price
- $13.46
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in equal annual installments over 4 years, with the first installment vesting on January 10, 2025 and the last installment vesting on January 10, 2028; subject to Reporting Person's providing continued service to Issuer through each vesting date.
Footnote F2
Includes 105,932 RSUs.
Footnote F3
The stock option vests in equal annual installments over 4 years, with the first installment vesting on January 10, 2025 and the last installment vesting on January 10, 2028, subject to Reporting Person's providing continued service to Issuer through each vesting date.
SEC remarks
*Chief Legal & Compliance Officer, Corporate Secretary